Elegance in Molecular Design

  • Highly TargeteD

  • Bi-specific, single agent

  • small molecule treatments

Header mobile v4.8.png

Technology built on two Novel platforms:


Anti-angiogenic & Anti-Tubulin

Small, water-soluble molecules for highly vascularized tumors. Designed to be dual-acting (anti-angiogenic and anti-tubulin) in a single agent. Developed for the treatment of Glioblastoma Multiforme and triple-negative breast cancer.

Purine Synthesis inhibitor

Highly potent, water-soluble molecules engineered to selectively bind to cancer cells and inhibit purine synthesis at multiple points. Developed for mesothelioma, ovarian, kidney, and pancreatic cancers.


Meet FLAG-003

Our lead Candidate


FLAG Therapeutics is developing a first-in-class, dual-acting, small molecule for the treatment of glioblastoma. FLAG-003 is a water-soluble, hybrid-scaffold elegantly designed to target cancer cells. With a unique dual mechanism of action, FLAG-003 is small enough to pass the blood-brain-barrier and is engineered to simultaneously block the formation of new blood vessels and kill cancer cells. 

*FLAG-003 is currently under investigational use.

Glioblastoma header 800x600 v2.png

Major Milestones

Awarded $1.5 M 2 year SBIR to study Purine Synthesis Inhibitors for the treatment of Mesothelioma

Successful pre-IND meeting with US FDA for FLAG-003

FLAG granted Orphan Drug Designation for FLAG-003 for the treatment of Glioma in both the US and EU.


FLAG To present at NYC oncology conference 10/30 @ 6pm

October 25, 2018

NC Biotech Center awards $500k Strategic Growth Loan

July 31, 2018

Header v5.1.png



Interested in FLAG's technology? Please send us a message and we'll be in touch.